Scarica l'app Stockscreener
4.64
1.69%
-0.08
Dopo l'orario di chiusura:
4.60
-0.04
-0.86%
Precedente Chiudi:
$4.72
Aprire:
$4.72
Volume 24 ore:
575.87K
Relative Volume:
1.24
Capitalizzazione di mercato:
$274.17M
Reddito:
$192.64M
Utile/perdita netta:
$2.51M
Rapporto P/E:
88.55
EPS:
0.0524
Flusso di cassa netto:
$12.42M
1 W Prestazione:
-1.28%
1M Prestazione:
+8.92%
6M Prestazione:
-3.53%
1 anno Prestazione:
-8.66%
Intervallo 1D:
$4.54
$4.74
Intervallo di 1 settimana:
$4.54
$4.92
Portata 52W:
$3.8092
$5.545
Vanda Pharmaceuticals Inc Stock (VNDA) Company Profile
Nome
Vanda Pharmaceuticals Inc
Settore
Industria
Telefono
202-734-3400
Indirizzo
2200 PENNSYLVANIA AVE NW, WASHINGTON
Confronta VNDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VNDA
Vanda Pharmaceuticals Inc
|
4.64 | 278.31M | 192.64M | 2.51M | 12.42M | 0.0524 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Vanda Pharmaceuticals Inc Stock (VNDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-10-31 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-11 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-25 | Downgrade | Jefferies | Buy → Hold |
| 2021-05-12 | Iniziato | BofA Securities | Buy |
| 2021-01-14 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-09 | Downgrade | Citigroup | Buy → Neutral |
| 2020-03-16 | Downgrade | Oppenheimer | Perform → Underperform |
| 2020-03-12 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-11-07 | Downgrade | Citigroup | Buy → Neutral |
| 2019-08-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-07-25 | Downgrade | Stifel | Buy → Hold |
| 2018-12-11 | Downgrade | Oppenheimer | Outperform → Perform |
| 2018-12-04 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2018-12-04 | Reiterato | Jefferies | Buy |
| 2018-11-08 | Ripresa | Jefferies | Buy |
| 2018-09-21 | Ripresa | Oppenheimer | Outperform |
| 2018-05-23 | Iniziato | Citigroup | Buy |
| 2018-01-19 | Iniziato | Seaport Global Securities | Buy |
| 2017-09-14 | Reiterato | Piper Jaffray | Overweight |
| 2017-06-27 | Ripresa | Piper Jaffray | Overweight |
| 2017-05-26 | Iniziato | H.C. Wainwright | Buy |
| 2017-04-12 | Iniziato | Oppenheimer | Outperform |
| 2016-11-09 | Iniziato | Aegis Capital | Buy |
| 2016-10-06 | Ripresa | Jefferies | Buy |
Mostra tutto
Vanda Pharmaceuticals Inc Borsa (VNDA) Ultime notizie
Vanda at Cantor Global: Strategic Growth Amid Challenges - Investing.com
Will Vanda Pharmaceuticals Inc. price bounce be sustainablePortfolio Performance Report & Verified Chart Pattern Signals - Newser
How to read the order book for Vanda Pharmaceuticals Inc.Wall Street Watch & Expert Verified Stock Movement Alerts - Newser
Why Vanda Pharmaceuticals Inc. is moving todayEarnings Recap Report & Accurate Technical Buy Alerts - Newser
Heatmap analysis for Vanda Pharmaceuticals Inc. and competitorsJuly 2025 Market Mood & Fast Exit Strategy with Risk Control - Newser
Should you wait for a breakout in Vanda Pharmaceuticals Inc.2025 Key Highlights & High Conviction Investment Ideas - Newser
What does recent volatility data suggest for Vanda Pharmaceuticals Inc.Portfolio Risk Summary & Verified Entry Point Signals - Newser
Key metrics from Vanda Pharmaceuticals Inc.’s quarterly dataWeekly Stock Report & Momentum Based Trading Ideas - Newser
Trend analysis for Vanda Pharmaceuticals Inc. this weekJuly 2025 Setups & Weekly High Return Forecasts - Newser
What the charts say about Vanda Pharmaceuticals Inc. today2025 Buyback Activity & AI Enhanced Trading Alerts - Newser
Regression analysis insights on Vanda Pharmaceuticals Inc. performanceWeekly Trend Recap & Community Trade Idea Sharing - Newser
Published on: 2025-09-03 01:35:02 - Newser
Is a relief rally coming for Vanda Pharmaceuticals Inc. holdersPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
Vanda Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Pullbacks & Growth Focused Stock Reports - Newser
Vanda Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Outlook & Real-Time Stock Price Movement Reports - Newser
Technical signs of recovery in Vanda Pharmaceuticals Inc.Weekly Profit Report & Fast Gaining Stock Reports - Newser
Can Vanda Pharmaceuticals Inc. benefit from deglobalizationWeekly Stock Analysis & Expert Verified Stock Movement Alerts - khodrobank.com
Tools to assess Vanda Pharmaceuticals Inc.’s risk profile2025 Market Outlook & Verified Swing Trading Watchlist - Newser
Using fundamentals and technicals on Vanda Pharmaceuticals Inc.Share Buyback & Capital Protection Trading Alerts - Newser
Why is Vanda Pharmaceuticals Inc. stock going upJuly 2025 Intraday Action & Weekly Sector Rotation Insights - khodrobank.com
Published on: 2025-09-01 13:55:21 - Newser
How institutional ownership impacts Vanda Pharmaceuticals Inc. stock2025 Price Targets & AI Optimized Trading Strategy Guides - Newser
Vanda Slams US FDA ‘Generic Bias,’ Again Seeks To Undo Hetlioz ANDA Approvals - insights.citeline.com
Is Vanda Pharmaceuticals Inc. stock a smart retirement pickJuly 2025 Intraday Action & Accurate Entry and Exit Point Alerts - khodrobank.com
Vanda Pharmaceuticals gets FDA orphan drug status for VGT-1849B - MSN
Vanda Pharmaceuticals Inc. recovery potential after sell offTrade Analysis Report & Expert Verified Stock Movement Alerts - Newser
Using Bollinger Bands to evaluate Vanda Pharmaceuticals Inc.Rate Cut & Low Drawdown Momentum Trade Ideas - Newser
Using Python tools to backtest Vanda Pharmaceuticals Inc. strategiesWeekly Gains Report & Low Risk Entry Point Tips - Newser
Understanding Vanda Pharmaceuticals Inc.’s price movementWeekly Gains Report & Risk Controlled Stock Pick Alerts - Newser
What momentum shifts mean for Vanda Pharmaceuticals Inc.2025 Price Targets & Precise Trade Entry Recommendations - Newser
Developing predictive dashboards with Vanda Pharmaceuticals Inc. dataMarket Growth Review & Growth-Oriented Investment Plans - Newser
Vanda Pharmaceuticals Inc Azioni (VNDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vanda Pharmaceuticals Inc Azioni (VNDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mitchell Stephen Ray | Director |
Jun 13 '25 |
Sale |
4.59 |
7,000 |
32,130 |
97,082 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):